Clinical Study Protocol AN4005X0101 An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients With Advanced Tumors
Latest Information Update: 11 Jul 2024
At a glance
- Drugs AN 4005 (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Peripheral T-cell lymphoma; Solid tumours; T-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors Adlai Nortye
- 27 Jun 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 27 Jun 2024 Planned primary completion date changed from 1 May 2024 to 1 Aug 2024.
- 07 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 May 2024.